NEW YORK (
) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow.
Highlights from the ratings report include:
- SLTM's revenue growth has slightly outpaced the industry average of 6.4%. Since the same quarter one year prior, revenues rose by 10.3%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.
- SLTM's debt-to-equity ratio is very low at 0.07 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.46, which illustrates the ability to avoid short-term cash problems.
- Compared to where it was trading a year ago, SLTM's share price has not changed very much due to (a) the relatively weak year-over-year performance of the overall market, (b) the company's stagnant earnings, and (c) other mixed results. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, SOLTA MEDICAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has significantly decreased to -$3.09 million or 226.56% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
Solta Medical, Inc., together with its subsidiaries, engages in the design, development, manufacture, and marketing of professional and consumer energy-based medical device systems for aesthetic applications. Solta Medical has a market cap of $133.8 million and is part of the
industry. Shares are down 29.2% year to date as of the close of trading on Monday.
You can view the full
or get investment ideas from our